The US Food and Drug Administration (FDA) has added Kantaro Biosciences’ COVID-SeroKlir antibody test to the emergency use authorisation (EUA) for convalescent plasma.

COVID-SeroKlir is a high-performance test for identifying the presence and precise level of SARS-CoV-2 IgG antibodies.

The revised EUA qualifies the test for detecting high titer Covid-19 convalescent plasma during manufacturing.

It limits the use of high titer Covid-19 convalescent plasma only for the treatment of hospitalised patients who are in the early stage of the disease.

Currently, Covid-19 convalescent plasma is an investigational product and is not approved or licenced for any indication.

The company noted that the test can detect SARS-CoV-2 IgG antibodies with a sensitivity of 98.8% and specificity of 99.6%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kantaro Biosciences board chairman Erik Lium said: “We are pleased the FDA has added Kantaro’s COVID-SeroKlir antibody test to the EUA for convalescent plasma and authorised the test’s use in qualifying convalescent plasma titers.

“We believe semi-quantitative antibody testing can play an important role in the development of advanced therapeutics for Covid-19 and appreciate that it is being recognised as such.”

The high performance of COVID-SeroKlir is the result of a two-step process, which identifies antibodies against two virus antigens, the full-length spike protein, and its receptor-binding domain.

It makes the Kantaro test precise with decreased chances for false results.

The test’s underlying technology was developed by Mount Sinai and has been used approximately 90,000 times on a highly diverse patient population.

Last November, the FDA granted EUA to COVID-SeroKlir.

Kantaro Biosciences and its manufacturing partner Bio-Techne have signed a marketing and distribution agreement with biomedical company Atrys Health for Covid-19 tests.